Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121804 | 0.85 | TYR (0.42) | L3MBTL1KDM4ERXFP1CNR1CNR2 | |
| SCHEMBL20709987 | 0.82 | PTGDR2 (0.33) | L3MBTL1RXFP1 | |
| SCHEMBL20709922 | 0.79 | BRD4 (0.37) | LMNAL3MBTL1KDM4ERXFP1CNR1 | |
| SCHEMBL20704500 | 0.79 | BRD4 (0.44) | L3MBTL1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL12659545 | 0.79 | RAPGEF4 (0.36) | LMNAKDM4EBRD4ALDH1A1NPY5R | |
| SCHEMBL20704421 | 0.78 | GRIA1 (0.33) | LMNAKDM4ERXFP1CNR1CNR2 | |
| SCHEMBL20506971 | 0.78 | PDE10A (0.32) | LMNAKDM4ECNR1CNR2BRD4 | |
| SCHEMBL20709921 | 0.78 | BRD4 (0.32) | L3MBTL1RXFP1BRD4 | |
| SCHEMBL15975215 | 0.78 | MAPT (0.36) | LMNAKDM4ERXFP1BRD4ALDH1A1 | |
| SCHEMBL20709986 | 0.77 | CNR1 (0.40) | LMNAKDM4ERXFP1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20200239437-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | BRISTOL MYERS SQUIBB CO (US) | 2020-07-30 | — | — | US | disclosed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2019028302-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| EP-2324018-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2300461-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | LMNA 916/4885L3MBTL1 2010/4885KDM4E 3273/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | LMNA 4494/4885L3MBTL1 2505/4885KDM4E 1039/4885 |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | LMNA 1902/4885L3MBTL1 2968/4885KDM4E 1154/4885 |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | LMNA 2338/4885L3MBTL1 3920/4885KDM4E 3461/4885 |
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | LMNA 1855/4885L3MBTL1 1457/4885KDM4E 160/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | LMNA 1745/4885L3MBTL1 3154/4885KDM4E 1262/4885 |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | LMNA 2403/4885L3MBTL1 3920/4885KDM4E 3441/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | LMNA 1855/4885L3MBTL1 1457/4885KDM4E 160/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | LMNA 2828/4885L3MBTL1 4021/4885KDM4E 3552/4885 |
| US-20200239437-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | TLR7, TLR9, TLR8 | LMNA 1819/4885L3MBTL1 3681/4885KDM4E 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.